Kuano introduces Quantum Lens technology
It unlocks undruggable targets using quantum chemistry and active learning. Successfully identified 3 novel chemotypes for DNMT1 from 40 compounds.
See the latest news and media coverage for Kuano. We track all announcements, press releases, and industry mentions in real time, all in one place.
Quantum simulation and AI drug discovery platform
kuano.aiLast updated
In short: Kuano advanced its quantum-enabled drug discovery platform, launched new technology, and secured $1.8M in seed funding to target complex enzymes.
It unlocks undruggable targets using quantum chemistry and active learning. Successfully identified 3 novel chemotypes for DNMT1 from 40 compounds.
The collaboration deploys Kuano's quantum-enabled platform to tackle challenging targets like PNKP. Kuano seeks additional partners for drug development bottlenecks.
It leverages quantum-informed representations and AI to explore novel chemistries. PharmacoJump and ActivityMapper map energetic drivers of activity.
It combines AI with physics-based models to accelerate discovery, tackle difficult targets, and de-risk pipelines via an integrated design engine and expert support.
Onco-Innovations Limited proudly announces the start of an ambitious pilot project, which is in close collaboration with...
Kuano welcomes David Barrett a scientific advisory board member. David is a senior-level R&D leader and drug hunter in the biopharma industry. He has been...
Kuano uses OCI to create drug design platform to benefit Alzheimer's research. The UK-based biotech research company enables better drug design...
By Ruth Coleman and Robert Hornby, investors at Mercia Ventures.
Track Kuano and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Kuano and other trending companies.